Disbrow Joshua R.'s Form 4 filing
Aytu Biopharma, Inc (AYTU) · filed Dec 21, 2022
- Accession no.
- 0001567619-22-021900
- Filed
- Dec 21, 2022, 9:17 AM ET
- Trade date
- Dec 19, 2022
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 1 non-derivative transaction. Open-market purchases total $25.0K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Disbrow Joshua R.CIK 0001566240 | Director, Officer (Chief Executive Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 19, 2022 | Common Stock | PPurchaseAcquired | +112,371 | $0.2229F1 | +$25,047.5 | 1,231,877 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The purchase price reported above is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.213 to $0.23, inclusive. The reporting person undertakes to provide to AYTU Biopharma, Inc., any security holder of AYTU Biopharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
Referenced by the price of 1 transaction in Table I.
Remarks
Exhibit 24.1 Power of Attorney